Clearing The Fog: Optimizing Cancer Trials With Cognitive Assessments

Cancer-related cognitive impairment (CRCI), often termed "chemo brain," significantly impacts cancer patients, affecting their memory, attention, and processing speed. This cognitive decline can occur before, during, or after treatment, with contributing factors ranging from chemotherapy and radiation to the cancer itself.

The Signant SmartSignals® Cognitive Drug Research (CDR) System® offers a groundbreaking solution, providing sensitive and comprehensive cognitive assessments across critical domains. This validated tool, supported by a robust normative database, enables real-time cognitive impairment tracking and analysis, helping identify high-risk patients and inform targeted interventions. Elevate your clinical trial protocols with tailored insights and improve patient outcomes through advanced cognitive monitoring.